One molecule, two product labels
Mounjaro and Zepbound both contain tirzepatide, a GIP and GLP-1 receptor agonist. Their US labels describe different uses and populations. The distinction is more precise than “diabetes brand versus weight-loss brand,” because current labeling includes additional outcomes and presentation options.
The brand on a prescription identifies a particular labeled product. Sharing a molecule does not make the packages a reader-directed substitution or mean every device and storage instruction is identical.
What the current labels say
| Brand | Labeled use | Population detail |
|---|---|---|
| Mounjaro | Glycemic control as an adjunct to diet and exercise | Adults and children age 10+ with type 2 diabetes. |
| Mounjaro | Reduction of major cardiovascular-event risk | Adults with type 2 diabetes at high risk for those events. |
| Zepbound | Long-term excess-weight reduction and maintenance with diet/activity | Adults with obesity, or overweight with a weight-related comorbid condition. |
| Zepbound | Moderate-to-severe obstructive sleep apnea | Adults with obesity. |
The cardiovascular use in Mounjaro’s August 2026 document makes older “adult glycemic control only” summaries incomplete. Zepbound’s sleep-apnea use is also a defined population and condition, not a general promise about every person’s sleep.
Identify the actual package
Current labels describe single-dose pens and vials as well as multidose vial and single-patient-use KwikPen presentations. Use the name and Instructions for Use on the dispensed package. Do not assume that an image of one device on an old article identifies the presentation in your prescription.
This is useful even for a simple trip checklist. Record the brand, presentation, unopened versus in-use status, required packaging and source of the storage instructions. A catalog case marketed for a familiar brand name is not physical proof that every current device or carton fits.
A pharmacist can help identify which document belongs to the package. Keep that identification separate from the clinical question of which product and indication fit a person’s circumstances.
The shared molecule does not simplify every decision
Both labels include a boxed warning regarding thyroid C-cell tumors, contraindications and important warnings, including gastrointestinal adverse effects and interactions. The full Medication Guide remains important even when the brand names are familiar.
Insurance coverage, dispensing availability and a person’s eligibility cannot be inferred from a label comparison. Nor does a current indication mean that a medicine should replace another treatment without a clinical review. Those questions depend on medical history and the actual care plan.
For reading a study, keep the molecule and product question apart. A tirzepatide trial in one population can provide valuable evidence, but the paper’s inclusion criteria and outcomes must still be read. It is not automatically evidence for every use on either brand’s current label.
A clear note for the next conversation
A question for the appointment could be: “I understand both names contain tirzepatide. Which exact indication are we discussing, and which presentation would the prescription specify? Where should I find its current storage and administration instructions?” That question asks for the information needed to understand a plan without making a switching decision from a web table.
Are Mounjaro and Zepbound different molecules?
No. Tirzepatide is the active molecule in both.
Does the same molecule mean the same labeled use?
No. Read the actual brand’s indication section and population limits.
Can this article establish cost or coverage?
No. It reports current US label distinctions, not an insurer decision, pharmacy stock or an individual prescription.
Read next
Sources and method
- Mounjaro prescribing information, August 2026 — current glycemic and cardiovascular indications.
- Zepbound prescribing information, August 2026 — adult weight-management/OSA indications and current presentations.
Sources checked October 29, 2026.
Prepared by GLP Finds with AI-assisted writing and checked against the listed sources. Our editorial process. This article has not received independent clinical review.